Anti-MAA antibody status was reported in a subset of clinical studies, with positivity defined using different thresholds (85th-99.4th percentile of control populations (21, 30, 31, 33, 37–39) or in the top two tertiles of RA participants (34)) with substantial variability in proportions of seropositive individuals observed. Here, NAA10 is linked to rheumatoid arthritis.